Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Research roundup: Reform's impact on health spending; Cultural/Racial differences in medicine; Swine flu lessons

The Impact Of Health Reform On Health Spending - This issue brief "projects the effect of national reform on total national health expenditures and the insurance premiums that American families would likely pay. We estimate that, on net, the combination of provisions in the new law will reduce health care spending by $590 billion over 2010-2019 and lower premiums by nearly $2,000 per family.

29 May 2010

MU awarded $6.8M to help patients benefit from use of health information technology

Considered one the great advances of modern medicine, electronic health records can provide a patient's entire medical history and a wealth of other information at the click of a button. They also have the potential to save countless lives and billions of dollars. Now, the University of Missouri has a two-year, $6.8 million cooperative agreement to help patients throughout the state benefit from increased use of this health information technology.

29 May 2010

VaxGen signs definitive agreement to acquire diaDexus in stock-for-stock merger

VaxGen, Inc., a biopharmaceutical company, and diaDexus, Inc., a privately held diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, announced today that they have entered into a definitive agreement under which VaxGen will acquire diaDexus in a stock-for-stock merger.

29 May 2010

Scientists offer low-cost solutions to reduce arsenic in drinking water

An estimated 60 million people in Bangladesh are exposed to unsafe levels of arsenic in their drinking water, dramatically raising their risk for cancer and other serious diseases, according to the World Health Organization.

28 May 2010

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

Regulus Therapeutics Inc. announced today that it has obtained exclusive rights from the University of Wuerzburg to intellectual property covering methods for modulating microRNA-21. Regulus scientists and collaborators have shown that microRNA-21, (miR-21), is dysregulated in mouse models of cardiac disease and fibrosis, and that antagonizing miR-21 with therapeutic oligonucleotides targeting miR-21 inhibits fibrosis and attenuates cardiac function in such models. Regulus is currently developing a microRNA therapeutic targeting miR-21 as an anti-fibrotic therapy.

28 May 2010

Individuals with poor oral hygiene at increased risk of heart disease

Individuals who have poor oral hygiene have an increased risk of heart disease compared to those who brush their teeth twice a day, finds research published today on BMJ.com.

28 May 2010

Dosage of statin drugs given to patients with heart disease should be monitored: Study

The type and dosage of statin drugs given to patients to treat heart disease should be proactively monitored as they can have unintended adverse effects, concludes a new study published on bmj.com.

27 May 2010

Weill Cornell Medical College commences construction of 18-story, $650 million Medical Research Building

Weill Cornell Medical College today celebrated the start of construction on its new Medical Research Building, a state-of-the-art facility that will more than double the institution's existing research space. The 18-story, $650 million building is the centerpiece of Weill Cornell's $1.3 billion Discoveries that Make a Difference Campaign, the country's largest for a medical college. A total of $1 billion has been raised toward this goal in a record time of less than four years.

27 May 2010

Traffic-related air pollution also increases risk of type 2 diabetes in women

Traffic-related air pollution, known to raise the risk for cardiovascular disease, may also increase the risk of developing type 2 diabetes in women. Low-grade inflammation may contribute to the higher incidence of type 2 diabetes in women exposed to air pollution, according to German researchers.

27 May 2010

Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors

Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2461629, titled, "HETEROALKYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS," which includes coverage of Amira's AM461 DP2 receptor antagonist.

27 May 2010

Health Canada approves Victoza for treatment of adults with type 2 diabetes

Diabetes is growing at an alarming rate in Canada, with an estimated 3.7 million people expected to be diagnosed by 2020. It is a progressive disease that, if not properly monitored and managed over time, will lead to serious long term complications. Canadians now have a novel treatment available to help them maintain optimal blood glucose levels. Health Canada has approved Victoza (liraglutide), the first GLP-1 analogue, for once-daily administration for the treatment of adults with type 2 diabetes to improve glycemic control in combination with metformin or metformin and a sulfonylurea.

27 May 2010

PBI awarded contract to provide essential laboratory data for Phase I cardiovascular trial

Pacific Biomarkers, Inc. has been awarded a contract by a leading multinational pharmaceutical company to provide essential laboratory data for an adaptive Phase I cardiovascular trial. This study is part of a major drug-development program to evaluate an innovative new treatment to reduce recurrent cardiovascular events associated with acute coronary syndrome.

27 May 2010

Rates of cardiovascular disease increase in Australian winters: Seasonal researcher

Rates of cardiovascular disease increase dramatically in Australian winters because many people don't know how to rug up against the cold, a Queensland University of Technology seasonal researcher has found.

27 May 2010

VisEn Medical announces launch of two new imaging agents at EMIM 2010

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced the commercial launch of two new imaging agents -- ProSense® 750 FAST for expanded versatility in imaging cathepsin activity, and Neutrophil Elastase™ 680 FAST, for imaging of inflammatory elastase activity associated with disease progression and therapeutic response. The launch announcements were made at the European Molecular Imaging Meeting (EMIM) 2010 in Warsaw, Poland.

26 May 2010

Good number of natural bypass vessels an 'insurance policy' against blockage

When the arteries delivering oxygen to our vital organs are obstructed by atherosclerosis or clots, the result is almost always a stroke, heart attack or damage to a peripheral tissue such as the legs (peripheral artery disease). But the severity of tissue injury or destruction from a choked-off blood supply varies from person to person, and may depend in large part on whose circulatory system has the best back-up plan to provide alternate routes of circulation.

26 May 2010

BMI in overweight range not a higher risk for health problems

A study examining the relationship between body mass index (BMI) and illness suggests that a BMI of 30 or above, a signal of obesity according to federal health standards, does not translate into current illness among adults under age 40.

26 May 2010

Medtronic’s Resolute zotarolimus-eluting stent as effective as Xience V everolimus-eluting stent: Study

The highly anticipated first results of the RESOLUTE All Comers study were presented today during the late-breaking clinical trial session of the 2010 EuroPCR meeting. In this novel 2,292-patient randomized trial, the Resolute zotarolimus-eluting stent from Medtronic, Inc. was found to be as safe and effective as the Xience® V everolimus-eluting stent from Abbott Laboratories.

26 May 2010

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

POZEN Inc., announced today the receipt of a $20 million milestone payment from AstraZeneca for the U.S. Food and Drug Administration approval of VIMOVO (naproxen and esomeprazole magnesium) delayed-release tablets on April 30th. POZEN will transfer ownership of the Investigational New Drug application and New Drug Application for VIMOVO to AstraZeneca over the next few weeks.

26 May 2010

PIONEER trial evaluates new safe concept of stent-drug combination

Blue Medical today announced a major step forward in its quest to improve the quality of life of patients with cardiovascular disease, with the start of the PIONEER trial, in which a new safe concept of stent-drug combination is evaluated.

26 May 2010

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, today announced the results of a study evaluating the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention Deficit Hyperactivity Disorder in adolescents aged 13 to 17 years.

26 May 2010

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Research roundup: Reform's impact on health spending; Cultural/Racial differences in medicine; Swine flu lessons

MU awarded $6.8M to help patients benefit from use of health information technology

VaxGen signs definitive agreement to acquire diaDexus in stock-for-stock merger

Scientists offer low-cost solutions to reduce arsenic in drinking water

Regulus Therapeutics obtains rights to intellectual property covering methods for modulating microRNA-21

Individuals with poor oral hygiene at increased risk of heart disease

Dosage of statin drugs given to patients with heart disease should be monitored: Study

Weill Cornell Medical College commences construction of 18-story, $650 million Medical Research Building

Traffic-related air pollution also increases risk of type 2 diabetes in women

Amira announces UK patent grant for heteroalkyl antagonists of prostaglandin D2 receptors

Health Canada approves Victoza for treatment of adults with type 2 diabetes

PBI awarded contract to provide essential laboratory data for Phase I cardiovascular trial

Rates of cardiovascular disease increase in Australian winters: Seasonal researcher

VisEn Medical announces launch of two new imaging agents at EMIM 2010

Good number of natural bypass vessels an 'insurance policy' against blockage

BMI in overweight range not a higher risk for health problems

Medtronic’s Resolute zotarolimus-eluting stent as effective as Xience V everolimus-eluting stent: Study

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

PIONEER trial evaluates new safe concept of stent-drug combination

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in